Predictive biomarkers for dasatinib treatment in melanoma
Open Access
- 1 January 2014
- journal article
- Published by Impact Journals, LLC in Oncoscience
- Vol. 1 (2) , 158-166
Abstract
Dasatinib has anti-proliferative and anti-invasive effects in melanoma cell lines. However clinical trials have shown modest activity for dasatinib in metastatic melanoma. Although dasatinib targets SRC kinase, neither expression nor phosphorylation of SRC appears to predict response to dasatinib. Identification of predictive biomarkers for dasatinib may facilitate selection of melanoma patients who are more likely to respond to dasatinib. We correlated the anti-proliferative effects of dasatinib in 8 melanoma cell lines with expression of a previously identified 6-gene biomarker panel. We examined the relationship between response to dasatinib and expression of each gene at both the mRNA and protein level. Dasatinib inhibited growth in 3 of the 8 cell lines tested. mRNA expression of the panel of 6 biomarkers did not correlate with response, whilst elevated protein expression of ANXA1, CAV-1 and EphA2 correlated significantly with response to dasatinib in the panel of cell lines. Expression of ANXA1, CAV-1 and EphA2 were analysed in 124 melanoma samples by immunohistochemistry. ANXA1 protein was detected in 81 % (97/120) of tumours, CAV-1 in 44 % (54/122) of tumours and EphA2 in 74 % (90/121) of tumours. Thirty one % (35/113) of tumours tested expressed all three markers and 19 % (21/112) had moderate or strong expression of ANXA1, CAV-1 and EphA2. Seventeen percent (19/112) of melanoma samples were positive for SRC kinase expression, combined with high expression of ANXA1, CAV-1 and EphA2. This subgroup may represent a population of melanoma patients who would be more likely to derive clinical benefit from dasatinib treatment.Keywords
This publication has 33 references indexed in Scilit:
- Nivolumab plus Ipilimumab in Advanced MelanomaNew England Journal of Medicine, 2013
- Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanomaBritish Journal of Cancer, 2011
- Redox-Induced Src Kinase and Caveolin-1 Signaling in TGF-β1-Initiated SMAD2/3 Activation and PAI-1 ExpressionPLOS ONE, 2011
- Src: a potential target for the treatment of triple-negative breast cancerAnnals of Oncology, 2011
- A phase 2 trial of dasatinib in advanced melanomaCancer, 2010
- High Levels of Exosomes Expressing CD63 and Caveolin-1 in Plasma of Melanoma PatientsPLOS ONE, 2009
- Annexin A2 Phosphorylation Mediates Cell Scattering and Branching Morphogenesis via Cofilin ActivationMolecular and Cellular Biology, 2008
- Identification of candidate predictive and surrogate molecular markers for dasatinib in prostate cancer: rationale for patient selection and efficacy monitoringGenome Biology, 2007
- Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasionMolecular Cancer Therapeutics, 2007
- Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/“triple-negative” breast cancer cell lines growing in vitroBreast Cancer Research and Treatment, 2007